2cureX AB (publ) (STO:2CUREX)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.340
-0.080 (-5.63%)
Mar 9, 2026, 4:50 PM CET
232.51%
Market Cap 33.64M
Revenue (ttm) 1.98M
Net Income (ttm) -26.35M
Shares Out 25.10M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend 0.08 (5.92%)
Ex-Dividend Date Jun 27, 2025
Volume 24,065
Average Volume 111,028
Open 1.420
Previous Close 1.420
Day's Range 1.335 - 1.420
52-Week Range 0.330 - 5.520
Beta 2.74
RSI 42.87
Earnings Date Feb 26, 2026

About 2cureX AB

2cureX AB (publ) operates as a medical technology company in Europe. The company’s principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient’s tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 14
Stock Exchange Nasdaq Stockholm
Ticker Symbol 2CUREX
Full Company Profile

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.

Financial Statements

News

There is no news available yet.